# US 2025/0375404 A1 · An orodispersible pharmaceutical composition of baclofen and its process of preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375404 A1
- Document ID: US20250375404A1
- Status: Published application
- Kind: A1
- Application number: 18/878,567
- Filed: 2023-06-21
- Published: 2025-12-11
- Earliest claimed: 2022-06-24
- Assignees: Novumgen Limited
- Applicants: Novumgen Limited
- Inventors: Kamleshkumar PATEL
- Web page: https://patentgrep.com/patent/US20250375404A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to orodispersible pharmaceutical composition suitable for oral administration comprising Baclofen with at least one disintegrant and at least one diluent. In the preferred embodiment Sodium starch glycolate is used as disintegrant in the range about in the range from about 1% w/w to about 10% w/w, preferably in the range from about 2% w/w to about 7.5% w/w. The present invention also relates to process for preparing the said solid pharmaceutical composition. The wet granulation process is used for the manufacturing process.

## Claims

### Claim 1

An orodispersible pharmaceutical composition suitable for oral administration comprising Baclofen at least one disintegrant and at least one diluent.

### Claim 2 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1, wherein baclofen is present in the range from 4% w/w to about 8% w/w, preferably in the range from about 5.5% w/w to about 7% w/w.

### Claim 3 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1, wherein disintegrant is selected from alginic acid, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose Sodium, croscarmellose sodium, guar gum, methylcellulose, polacrilin potassium, poloxamer, Sodium alginate and sodium starch glycolate or combination thereof.

### Claim 4 (depends on 3)

The orodispersible pharmaceutical composition according to claim 3, wherein disintegrant is sodium starch glycolate present in the range about in the range from about 1% w/w to about 10% w/w, preferably in the range from about 2% w/w to about 7.5% w/w.

### Claim 5 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1, wherein diluent is selected from microcrystalline cellulose, dextrates, dextrose, fructose, mannitol, Sorbitol, starch, pregelatinized starch, Sucrose, Xylitol, maltose, maltodextrin, maltitol or combinations thereof.

### Claim 6 (depends on 5)

The orodispersible pharmaceutical composition according to claim 5, wherein diluent is combination of Microcrystalline cellulose and mannitol present in the range from about 30% w/w to about 99% w/w, preferably from about 60% w/w to about 90% w/w.

### Claim 7 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable excipient selected from sweetener, flavouring agent, binder and lubricant.

### Claim 8 (depends on 7)

The orodispersible pharmaceutical composition according to claim 7, further comprising Low substituted hydroxypropyl cellulose (L-HPC), Orange flavor, Aspartame and Magnesium stearate.

### Claim 9 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1 is for treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, muscular rigidity and in patients with spinal cord injuries and other spinal cord diseases.

### Claim 10 (depends on 1)

A method for preparing an orodispersible pharmaceutical composition of Baclofen of claim 1, method comprising:
i. weighing all raw materials individually as per the batch formula;
ii. sieving mannitol, Microcrystalline cellulose 102, sodium starch glycolate, separately through #40 sieve and Aspartame, orange flavor, and magnesium stearate, separately through #60 sieve;
iii. preparing binder solution by dissolving L-HPC in sufficient quantity of purified water and make a clear binder solution;
iv. dry mixing of Baclofen, mannitol, and microcrystalline cellulose in the rapid mixer granulator;
v. adding binder solution gradually in dry mixed blend in rapid mixer granulator with continuance mixing;
vi. drying the granulated blend in a dryer at 50° C.±5° C.;
vii. passing dry granules through #24 sieve and retained granules milled through multi-mill and till all granules pass through #24 sieve;
viii. mixing of granules with previously shifted Mannitol, sodium starch glycolate, aspartame, orange flavour in the blender;
ix. mixing of the blend prepared in step (viii) with magnesium stearate in a blender; and
x. compressing the resulted mixture into tablet dosage form.

### Claim 11 (depends on 10)

The method for preparing an orodispersible pharmaceutical composition of Baclofen of according to claim 10 is wet granulation method.

### Claim 12 (depends on 1)

The orodispersible pharmaceutical composition according to claim 1, wherein the disintegrating time is less than 3 minutes preferably less than 1 minute.
